Faculty of Health/School of Medicine, Witten/Herdecke University, Witten, Germany.
University Children's Hospital, Tübingen University, Tübingen, Germany.
BMJ Open. 2023 Jun 23;13(6):e072722. doi: 10.1136/bmjopen-2023-072722.
Vaccinations are considered to have a large impact on disease control, hence a multitude of vaccines in infancy is recommended. Retrospective studies suggest a possible relation between timing, kind or number of vaccines given in the first year of life and the subsequent incidence of allergic diseases. It must be clarified whether a causal relationship exists to ensure safety and reduce vaccine hesitancy.
Due to the high recommendation rate of vaccines, a long-term randomised controlled trial is not considered as ethically acceptable. Therefore, this study aims to observe prospectively the allergic incidence at the age of 5 years after various vaccine interventions in the early months of life.Parents of infants up to the age of 4-6 weeks will be recruited before the first recommended vaccination. Relevant prognostic factors for allergies, status of immunisation and general health will be evaluated up to the age of 5.Allergic symptoms will be assessed by the International Study of Asthma and Allergies in Childhood-questionnaire and a medical confirmation of the allergy is mandatory.The main objective is to compare the incidence of asthma, atopic dermatitis, rhinoconjunctivitis, food allergy or any of these atopies at the age of 5 between infants who were not vaccinated or were vaccinated according to recommendations in the first year of life.The sample size calculation with about 4000 participants can prove a 5% difference to the basic prevalence with about 80% power and global 5% alpha error for the five primary endpoints adjusting according to Bonferroni-Holm and assuming a rate of 10% not early vaccinated infants.
The study was registered (DRKS00029677) and has received approval by the ethics committee of Universität Witten/Herdecke (no. 113/2022). The results will be published.
疫苗接种被认为对疾病控制有重大影响,因此建议在婴儿期接种多种疫苗。回顾性研究表明,婴儿期第一年接种疫苗的时间、种类或数量与随后过敏疾病的发生之间可能存在关联。必须明确是否存在因果关系,以确保安全性并减少疫苗犹豫。
由于疫苗推荐率很高,因此不认为长期随机对照试验在伦理上是可接受的。因此,本研究旨在前瞻性观察生命早期接受各种疫苗干预后 5 岁时的过敏发生率。将在首次推荐接种前招募 4-6 周龄以下婴儿的父母。将评估与过敏相关的预后因素、免疫状况和一般健康状况,直至 5 岁。通过国际儿童哮喘和过敏研究问卷调查评估过敏症状,并需要对过敏进行医学确认。主要目标是比较未接种疫苗或按照生命第一年推荐方案接种疫苗的婴儿在 5 岁时哮喘、特应性皮炎、鼻结膜炎、食物过敏或任何这些过敏症的发生率。大约 4000 名参与者的样本量计算可以证明在五个主要终点(根据 Bonferroni-Holm 进行调整并假设 10%的未早期接种婴儿率)上,与基本流行率相比有 5%的差异,具有约 80%的功效和全球 5%的 alpha 错误。
该研究已注册(DRKS00029677),并已获得威滕/赫德克大学伦理委员会的批准(编号 113/2022)。研究结果将公开发布。